This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. UroGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.461. UroGen Pharma's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.
As of today (2026-07-01), UroGen Pharma's share price is €30.97. UroGen Pharma's Median PS Value is €0.00. Therefore, UroGen Pharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for UroGen Pharma's Median PS Value or its related term are showing as below:
FRA:UR8's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
UroGen Pharma (FRA:UR8) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
UroGen Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
30.97
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma Median PS Value Related Terms
UroGen Pharma Median PS Value Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs SEPN, FTRE, MLTX: Median PS Value Comparison
For the Biotechnology subindustry, UroGen Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
UroGen Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.461.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Median PS Value of €0.00 as of Jul. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #999999 out of 277 companies in the Biotechnology industry.
Is UroGen Pharma's Median PS Value too high?
UroGen Pharma's current Median PS Value is €0.00. Based on the distribution chart, UroGen Pharma ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Median PS Value compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #999999 out of 277 companies for Median PS Value. This places UroGen Pharma in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.96, compared to a current price of €30.97 — trading 82.6% above its estimated fair value. The current Median PS Value is €0.00. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Median PS Value is €0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €30.97 is trading 82.6% above its estimated GF Value™ of €16.96.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Median PS Value: €0.00
GF Value™: €16.96 vs. price of €30.97 (82.6% above fair value)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score
Get the complete analysis for FRA:UR8
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
